Teva Pharmaceutical Industries Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Teva Pharmaceutical Industries Limited generated cash of $1,368,000,000, which is less than the previous year. Cash used in financing activities reached the amount of -$1,913,000,000 last year. Net change in cash is therefore $393,000,000.
Cash Flow
| 2014 | 5.12B | -1.45B | -2.37B |
|---|---|---|---|
| 2015 | 5.54B | -5.56B | 4.80B |
| 2016 | 5.22B | -35.74B | 25.21B |
| 2017 | 3.50B | 2.16B | -5.75B |
| 2018 | 2.44B | 1.86B | -3.35B |
| 2019 | 538M | 430M | -241M |
| 2020 | 1.21B | 863M | -1.88B |
| 2021 | 798M | 1.52B | -2.17B |
| 2022 | 1.59B | 656M | -1.48B |
| 2023 | 1.36B | 968M | -1.91B |
TEVA Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 2.83B | 2.19B | 2.17B | 1.97B | 1.24B | 963M | 988M | 6.94B | 2.22B | 1.03B |
Operating activities | ||||||||||
Net income | -615M | -2.40B | 456M | -4.09B | 76M | -2.47B | -16.44B | 311M | 1.59B | 3.04B |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.15B | 1.30B | 1.33B | 1.55B | 416M | 1.84B | 2.11B | 1.52B | 1.30B | 1.50B |
Stock-based compensation expense | 121M | 124M | 119M | 129M | 20M | 155M | 133M | 124M | 117M | 95M |
| Deferred income tax benefit | 121M | 124M | 119M | 129M | 20M | 155M | 133M | 124M | 117M | 95M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 12M | 334M | -574M | -293M | -394M | 88M | 514M | 343M | 763M | 710M |
Inventories | 0 | -163M | 380M | 41M | 271M | 26M | 266M | 753M | 129M | 230M |
Accounts payable | 1.58B | 1.91B | 764M | -463M | 643M | -500M | -1.80B | 640M | -12M | -614M |
Cash generated by operating activities | 1.36B | 1.59B | 798M | 1.21B | 538M | 2.44B | 3.50B | 5.22B | 5.54B | 5.12B |
Investing activities | ||||||||||
Purchases Of Investments | -46M | -1M | -47M | -55M | -3M | -119M | -200M | -481M | -2.00B | -324M |
Investments In Property Plant And Equipment | -526M | -548M | -562M | -578M | -119M | -651M | -874M | -901M | -772M | -929M |
Acquisitions Net | 68M | 61M | 1.95B | 67M | -343M | 1.73B | 43M | -36.14B | -3.30B | -363M |
Cash generated by investing activities | 968M | 656M | 1.52B | 863M | 430M | 1.86B | 2.16B | -35.74B | -5.56B | -1.45B |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 329M | 3.29B | 129M |
Payments for dividends | 0 | 0 | 0 | 0 | -52M | -22M | -1.16B | -1.55B | -1.15B | -1.15B |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27.61B | -439M | -500M |
Repayments of term debt | -1.70B | -1.36B | -7.84B | -2.43B | -1.86B | -7.44B | -4.47B | -999M | -393M | -839M |
Cash used in financing activities | -1.91B | -1.48B | -2.17B | -1.88B | -241M | -3.35B | -5.75B | 25.21B | 4.80B | -2.37B |
Net Change In Cash | 393M | 636M | 21M | 202M | 734M | 819M | -25M | -5.95B | 4.72B | 1.18B |
Cash at end of period | 3.22B | 2.83B | 2.19B | 2.17B | 1.97B | 1.78B | 963M | 988M | 6.94B | 2.22B |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |